[1] Goronzy JJ, Weyand CM. T-cell co-stimulatory pathways in autoimmunity. Arthritis Research and Therapy. 2008;10(1, article S3).
[2] Alex Bishop G, Bertolino PD, Bowen DG,et al.Tolerance in liver transplantation.Best Pract Res Clin Gastroenterol.2012;26(1):73-84.
[3] Rook M, Rand E.Predictors of long-term outcome after liver transplant.Curr Opin Organ Transplant.2011;16(5):499-504.
[4] Li DH, Havell EA, Brown CL, et al.Woodchuck lymphotoxin-alpha, beta and tumor necrosis factor genes: structure, characterization and biological activity.Gene.2000 25;242(1-2):295-305.
[5] Nedwin GE, Naylor SL, Sakaguelli AY, et al. Human lymphotoxin and tumorNecerosis factor genes: structure、homology and chromosomal localization. Nueleie Acids Res.1985;13(17):6361.
[6] Bagul A.Ischaemic/reperfusion injury: Role of infliximab.World J Transplant.2012;2(3)35-40.
[7] El-Gezawy EM, Eldin EN, Mohamed WS,et al.Tumor necrosis factor-alfa and monocyte chemoattractant protein-1 gene polymorphisms in kidney transplant recipients.Saudi J Kidney Dis Transpl.2013;24(4):688-695.
[8] Roek CS,Lowry SF. Tumor necrosis factor-alpha.J Surg Res. 1991;51(5):434-445.
[9] The Ministry of Science and Technology of the People’s Republic of China. Guidance Suggestions for the Care and Use of Laboratory Animals. 2006-09-30.
[10] Allain JE, Mahieu-Caputo D, Loux N, et al.Impronement of Orthotopic Liver Transplantation Model in Rhesus Monkey.Chin J Bases Clin General Surg.2010;3(4):212-219.
[11] 冉江华,李铸,刘静,等.二袖套法建立恒河猴原位肝移植的稳定模型[J].中国组织工程研究,2011,15(5):62-768.
[12] Busuttil RW, Lake JR.Role of tacrolimus in the evolution of liver transplantation. Transplantation.2004;77(9 suppl):S44-51.
[13] Racusen LC,Halloran PF,Solez K.Banff 2003 meeting report:new diagnostic insights and standards.Am J Transplant.2004;4(10):1562-1566.
[14] Solez K. History of the Banff classification of allograft pathology as it approaches its 20th year.Curr Opin Organ Transplant.2010;15(1):49-51.
[15] Rüdiger T, Höfler H, Kreipe HH,et al.Quality assurance in immunohistochemistry: results of an interlaboratory trial involving172 pathologists.Am J Surg Pathol.2002;26(7): 873-882.
[16] Dickson C.Protein techniques: immunoprecipitation, in vitro kinase assays, and Western blotting.Methods Mol Biol.2008;461:735-744.
[17] Matsunaga K, Mashiba H. Augmentation of TNF-and lymphotoxin-mediated cytotoxic effect in the combined use of ACNU and involvement of oxygen free radicals.Gan To Kagaku Ryoho.1990;17(3pt2):452-458.
[18] Matsubara N,Fuehimoto S,Orita K.Differing roles of Protein kinase C on the antiProliferative effects of tumor necrosis factor alpha and beta on LoVo cell.Pathobiology.1990;58(3):168-171.
[19] Koga Y, Matsuzaki A, Suminoe A,al et.Neutrophil-derived TNF-related apoptosis-inducing ligand (TRAIL): a novel mechanism ofantitumor effect by neutrophils.Cancer Res. 2004; 64(3):1037-1043.
[20] Futosi K, Fodor S, Mócsai A. Neutrophil cell surface receptors and their intracellular signal transduction pathways. Int Immunopharmacol.2013;17(3):638-650.
[21] Bradley JR. TNF-mediated inflammatory disease. J Pathol. 2008;214(2):149-160.
[22] Girnita DM, Webber SA, Zeevi A. Clinical impact of cytokine and growth factor genetic polymorphisms in thoracic organ transplantation.Clin Lab Med.2008;28(3):423-440.
[23] Cardoni RL, Prigoshin N, Tambutti ML. Regulatory cytokines in the response to the allogeneic renal transplant. Medicina (B Aires).2005;65(1):54-62.
[24] Kita Y, Iwaki Y, Noguehi K, et al. Daily serum infianunatory cytokine (turnor necrosis factor-a, interleukin-6) monitoring in liver transplantation focusing on all graft rejection:a five-case report. Transplant Proc.1996;28(3):1237.
[25] Heidt S, San Segundo D, Shankar S.Peripheral blood sampling for the detection of allograft rejection: biomarker identification and validation.Transplantation.2011;92(1):1-9.
[26] Imagawa DK, Millis JM, Olthoff KM, et al.The role of tumor necrosis factor in allograft rejection. TransPlantation.1990; 50(2): 219-225.
[27] Pascher A, Klupp J.Biologics in the treatment of transplant rejection and ischemia/reperfusion injury: new applications for TNFalpha inhibitors? BioDrugs.2005;19(4):211-231.
[28] Rokahr KL, MeCaughan GW, NaPoli J, et al. Quantitation of eytokine Mrna Expression in biopsies from human liver allograft by a novel reverse transeriptase/polymerase chain reaetion method. Trans Plant Proe.1995;27(3):2148.
[29] Hoffmann MW, Wonigeit K, Steinlloff G, et al.Production of cytokines(TNF-α,IL-lβ)And endothelial cell aetivation in human liver allograft rejeetion.TransPlantation.1993;55(2):329-335.
[30] Basista MH, Stieffenllofer A, Kim DG, et al. Proeoagulant aetivity and tumor necrosis factor in rat hepatic allograft rejection.HePatology.1991;14(5):883-887.
[31] Adams DH, Garner C, Neuberger JM. Serum tumor necrosis factor alpha in Patients following liver transplantation. Trans Plant Proe.1990;22(5):2310.
[32] Imagawa DK, Millis JM, Olthoff KM,et al.The role of tumor necrosis factor in allograft rejection. I. Evidence that elevated levels of tumor necrosis factor-alpha predict rejection following orthotopic liver transplantation.Transplantation.1990;50(2):219-225.
[33] Fugger R, Hamilton G, Steininger R, et al. Intra operative estimation of endotoxin,TNF-a,and IL-6 in orthotopic liver transplantation and the irrelation to rejection and post operative infection. TransPlantation.1991;52(2):302.
[34] Bathgate AJ, Praviea V, Perrey C, et al. The effect of polymorphisms in tumor necrosis factor-alpha, interleukin-10, and transforming growth factor beta genes in acut hepatic allograft rejeetion. Transplantation.2000;69(7):1514.
[35] Flach R, Speidel N, Flohé S, et al. Analysis of intragraft cytokine expression during early reperfusion after liver transplantation using semi-quantitative RT-PCR.Cytokine.1998;10(6):445-451. |